Erasca, Inc.
ERAS
주식 순위
#3397
Erasca, Inc. is a biopharmaceutical company in the clinical development stage,... Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
주가
$14.51
마지막 동기화: 2026-10-21
시가총액
$5.08B
변동 (1일)
-0.75%
변동 (1년)
539.21%
국가
US
거래 Erasca, Inc. (ERAS)
카테고리
Healthcare
Erasca, Inc. (ERAS)의 주가 이력
최고 종가: $14.66 (2026-10-01 기준)
최저 종가: $19.40 (2021-07-01 기준)
최저 종가: $19.40 (2021-07-01 기준)
Erasca, Inc.의 주가 이력 (2021 ~ 2026)
연간 주가 성과
| 연도 | 성과 |
|---|---|
| 2026 (TTM) | 260.18% |
| 2025 | 24.72% |
| 2024 | 41.38% |
| 2023 | -63.49% |
| 2022 | -62.73% |
| 2021 | 0.00% |
유사 기업 또는 경쟁사의 주가
| 회사 | 주가 | 변동률 1년% | 국가 |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.77 | -3.82% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
